Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Erlotinib and Atezolizumab in Advanced HLRCC or Sporadic Papillary RCC
NCT04981509Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab and erlotinib in hereditary leiomyomatosis and renal cell cancer (HLRCC) and papillary renal cell carcinoma (PRCC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Objective response rate and 5 more. Started Jun 2022; status: recruiting.
02
Drugs
atezolizumabbevacizumaberlotinib
03
Conditions
hereditary leiomyomatosis and renal cell cancer (HLRCC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT04981509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981509.